Your browser doesn't support javascript.
loading
Antibodies against the erythroferrone N-terminal domain prevent hepcidin suppression and ameliorate murine thalassemia.
Arezes, João; Foy, Niall; McHugh, Kirsty; Quinkert, Doris; Benard, Susan; Sawant, Anagha; Frost, Joe N; Armitage, Andrew E; Pasricha, Sant-Rayn; Lim, Pei Jin; Tam, May S; Lavallie, Edward; Pittman, Debra D; Cunningham, Orla; Lambert, Matthew; Murphy, John E; Draper, Simon J; Jasuja, Reema; Drakesmith, Hal.
Afiliação
  • Arezes J; MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom.
  • Foy N; BioMedicine Design, Pfizer Biotherapeutics R&D, Dublin, Ireland.
  • McHugh K; Jenner Institute, University of Oxford, Oxford, United Kingdom.
  • Quinkert D; Jenner Institute, University of Oxford, Oxford, United Kingdom.
  • Benard S; BioMedicine Design, Pfizer Biotherapeutics R&D, Cambridge, MA.
  • Sawant A; Rare Disease Research Unit, Pfizer Inc., Cambridge, MA.
  • Frost JN; MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom.
  • Armitage AE; MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom.
  • Pasricha SR; MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom.
  • Lim PJ; Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.
  • Tam MS; Department of Medical Biology, The University of Melbourne, Melbourne, VIC, Australia; and.
  • Lavallie E; MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom.
  • Pittman DD; Rare Disease Research Unit, Pfizer Inc., Cambridge, MA.
  • Cunningham O; Rare Disease Research Unit, Pfizer Inc., Cambridge, MA.
  • Lambert M; Rare Disease Research Unit, Pfizer Inc., Cambridge, MA.
  • Murphy JE; BioMedicine Design, Pfizer Biotherapeutics R&D, Dublin, Ireland.
  • Draper SJ; BioMedicine Design, Pfizer Biotherapeutics R&D, Dublin, Ireland.
  • Jasuja R; Rare Disease Research Unit, Pfizer Inc., Cambridge, MA.
  • Drakesmith H; Jenner Institute, University of Oxford, Oxford, United Kingdom.
Blood ; 135(8): 547-557, 2020 02 20.
Article em En | MEDLINE | ID: mdl-31899794
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Talassemia / Citocinas / Anticorpos Neutralizantes / Hepcidinas / Proteínas Musculares Limite: Animals / Humans / Male Idioma: En Revista: Blood Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Reino Unido
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Talassemia / Citocinas / Anticorpos Neutralizantes / Hepcidinas / Proteínas Musculares Limite: Animals / Humans / Male Idioma: En Revista: Blood Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Reino Unido